Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label Dose Escalating Study of HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody With Dual Fc Domains, in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

NCT07491900 is registered in ClinicalTrials.gov with Hinge Bio as lead sponsor.

NCT NCT07491900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07491900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label Dose Escalating Study of HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody With Dual Fc Domains, in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
Lead sponsor
Hinge Bio
Phase
Phase 1
Overall status
Recruiting
Start date
March 23, 2026
Completion date
October 24, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extra-renal lupus (erl), lupus nephritis (ln), systemic lupus erthematosus (sle)